PRNewsWire
07 Oct 2025, 12:47 UTC · 49w ago
Verdict
Headline takes no side. We score CTOR +0.80 across three claims — strongly bullish.
+0.80strongly bullish
More positive than 88% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
Citius Oncology has entered an exclusive distribution agreement with Integris Pharma S.A. to provide LYMPHIR via Named Patient Programs across Greece, Cyprus, and several Balkan countries.
More positive than 77% of claims this week
Citius Oncology is actively engaging with prospective distribution partners to expand LYMPHIR access via Named Patient Programs in additional EU member states, South America, and the Middle East.
So whatSignals a broader global scaling strategy and potential for further partnership announcements across multiple continents.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 65% of claims this week
The company is utilizing Named Patient Programs (NPPs) to provide early access to LYMPHIR in markets where full commercial approval has not yet been granted.
More positive than 54% of claims this week
Which stocks this story touches
More positive than 88% of ticker scores this week
The company is expanding international access to its drug LYMPHIR through new distribution agreements and Named Patient Programs.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
7h ago
−53.1%
Price is moving against the score
$0.8774 vs $1.87 close before publication (Oct 6) · not market-adjusted
CTOR chart →
